Trefoil Therapeutics Begins Second Phase 2 “STORM” Clinical Trial with Regenerative Treatment for Fuchs Endothelial Corneal Dystrophy

Excerpt from the Press Release:

SAN DIEGO–(BUSINESS WIRE)–Trefoil Therapeutics today announced it has begun a Phase 2 clinical trial of its engineered Fibroblast Growth Factor-1, TTHX1114, to evaluate its safety and efficacy as a regenerative treatment for patients with Fuchs Endothelial Corneal Dystrophy (FECD). The “STORM” study, the second clinical trial of TTHX1114, is designed to assess its potential to enhance corneal recovery and improve visual acuity in FECD patients undergoing Descemetorhexis without Endothelial Keratoplasty (DWEK), which is also referred to as Descemet Stripping Only (DSO), for their disease.

DSO is a surgical procedure which involves the removal of unhealthy endothelial cells and guttae (collagen bodies produced by stressed endothelial cells) in a small central area of the cornea.

“DSO is emerging as a promising alternative to corneal transplantation,” said Francis W. Price, Jr., MD, founder and president of Price Vision Group and the Cornea Research Foundation of America (Indianapolis, IN), and an investigator in the trial. “The procedure relies on the patient’s endothelial cells to migrate and repopulate the region where the cells have been removed to improve the patient’s vision. TTHX1114 is an exciting new option to help endothelial cells regenerate in corneas, and it has the potential to help many people. We are honored to have Price Vision Group participate in this study.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release